COMMUNIQUÉS West-GlobeNewswire

Ipsen announces issuance of €500 million inaugural Rated Public Bond
19/03/2025
Transaction follows Investment Grade ratings assignment from both S&P and Moody’s PARIS, FRANCE, 19 March 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today announced [...]
Ipsen annonce le succès de son émission obligataire inaugurale notée d'un montant de 500 millions d'euros
19/03/2025
Cette transaction fait suite à l’attribution, par S&P et Moody’s, de notations de crédit ‘Investment Grade’ PARIS, FRANCE, 19 mars 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), groupe biopharmaceutique mondial de [...]
Primo Partners with ABX to Bring PB01 Closer to Taiwan’s Prostate Cancer Market
19/03/2025
TAIPEI, Taiwan, March 19, 2025 (GLOBE NEWSWIRE) -- In response to the growing burden of prostate cancer in Taiwan, Primo Biotechnology Co., Ltd. (“Primo”) has formed a strategic partnership with Germany-based ABX [...]
Prime Biome Reviews (Is It Safe And Legit To Use?) What Do PrimeBiome Consumer Reports Say About Its Efficacy?
19/03/2025
ST. PETERSBURG, Fla., March 19, 2025 (GLOBE NEWSWIRE) -- Prime Biome is a formulated gummy supplement that helps improve skin quality by targeting the root cause that worsens it. It supports skin cell turnover and [...]
HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China
19/03/2025
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) and Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), today [...]
Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K
18/03/2025
SARASOTA, Fla., March 18, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, today announced the [...]
HIV and Syphilis Testing Just Got Faster: bioLytical Launches the 1-Minute INSTI® Multiplex HIV-1/2 Syphilis Antibody Test in Australia
18/03/2025
The fastest rapid dual test for HIV and syphilis is now available in Australia, expanding access to reliable and accessible screening. A Major Step Forward in Infectious Disease Screening The INSTI® Multiplex HIV-1/2 [...]
Cytek® Biosciences Expands Cell Analysis Offerings with the Affordable, User-Friendly Cytek® Muse® Micro System
18/03/2025
Increasing Accessibility for Flow Cytometry Applications in Emerging and Established Markets FREMONT, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Today, Cytek Biosciences, Inc. (Nasdaq: CTKB) announced that it has added [...]
BioSyent Announces Grant of Restricted Share Units
18/03/2025
MISSISSAUGA, Ontario, March 18, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a grant of 56,767 Restricted Share Units “RSUs” to [...]
Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs
18/03/2025
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host [...]
Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs
18/03/2025
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host [...]
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
18/03/2025
August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Company expects to [...]
Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
18/03/2025
Significant progress in preclinical pipeline targeting KRAS-driven solid tumor cancers with systemic administration demonstrating robust anti-tumor and anti-metastasis activity in orthotopic mouse models; Recent funding [...]
Kalaris Announces Closing of Merger with AlloVir
18/03/2025
Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina [...]
Maravai Lifesciences Reports Fourth Quarter and Full Year 2024 Financial Results
18/03/2025
Schedules Conference Call for Thursday, March 20, 2025 SAN DIEGO, March 18, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services [...]
IR-MED CEO Issues Letter to Shareholders: Expanding Our Platform and Presenting New Clinical Data from Israel and the U.S.
18/03/2025
Rosh Pina, Israel, March 18, 2025 (GLOBE NEWSWIRE) -- IR-MED Inc. (“IR-MED” or the “Company”) (OTCQB: IRME), a developer of noninvasive, AI-driven spectrographic analysis technology addressing significant healthcare [...]
Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025
18/03/2025
IRVINE, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it will report fourth quarter 2024 financial results after the market [...]
Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
18/03/2025
Pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L metastatic breast cancer on track for top-line data in 2026 Pivotal Phase 3 OPERA-02 trial of palazestrant in combination with [...]
Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results
18/03/2025
SAN MATEO, Calif., and CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a biopharmaceutical company, today reported fourth quarter and full year 2024 financial results. Fourth [...]

Pages